Futibatinib is a targeted anti-cancer drug, and its use must strictly follow contraindications, foods, and restrictions to ensure efficacy and safety. The following text will systematically explain relevant contraindications and provide clear guidance for clinical medication.

1. Taboo population

(1) Pregnant women: Animal studies have shown embryotoxicity, which may cause fetal malformation or death. Before medication, it is necessary to confirm the pregnancy status and take contraceptive measures.

(2) Breastfeeding women: Medications may be secreted through breast milk. Breastfeeding should be temporarily suspended during treatment and for one week after discontinuation to avoid infant exposure risks.

(3) For patients with severe liver function impairment: Child Pugh C grade patients should avoid using it as drug metabolism may be significantly inhibited, leading to toxic accumulation.

2. Forbidden foods

(1) Grapefruits and their products: contain strong CYP3A4 inhibitors, which may increase the blood concentration of Fubatinib and increase the risk of adverse reactions.

(2) St. John's wort: As a CYP3A4 inducer, it may reduce drug efficacy and should be avoided for simultaneous intake.

3. Restrictive conditions

(1) Liver function monitoring: For patients with mild to moderate liver dysfunction, a reduction of 25% -50% is required, and ALT/AST should be monitored weekly until stable.

(2) Drug interactions: Avoid using CYP3A4 potent inhibitors (such as ketoconazole) or inducers (such as rifampicin) in combination, and adjust the dosage if necessary.

(3) Surgical restrictions: Medication must be stopped for at least 7 days before major surgery, and can only be resumed after the wound has fully healed after surgery.